(6-氨基吡啶-2-基)(1-甲基哌啶-4-基)甲酮.双盐酸盐 | 613678-10-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (6-氨基吡啶-2-基)(1-甲基哌啶-4-基)甲酮.双盐酸盐
• 英文名称: (6-Aminopyridin-2-yl)(1-methylpiperidin-4-yl)methanone dihydrochloride
• 英文别名: (6-aminopyridin-2-yl)-(1-methylpiperidin-4-yl)methanone;dihydrochloride
• CAS: 613678-10-7
• 化学式: C12H19Cl2N3O
• 分子量: 292.2
• InChiKey: HOWMFJAGZXHDHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.03
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.2
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] COMPOSITIONS AND METHODS OF SYNTHESIS OF PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS<br/>[FR] COMPOSITIONS ET MÉTHODES DE SYNTHÈSE D'AGONISTES DES RÉCEPTEURS 5-HT1F DÉRIVÉS DE LA PYRIDINOYLPIPÉRIDINE
  申请人：COLUCID PHARMACEUTICALS INC

  公开号：WO2011123654A1

  公开（公告）日：2011-10-06

  The present invention provides a novel polymorph of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide (Form A) characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure. This polymorph is useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine. The invention also provides a process for the synthesis of pyridinoylpiperidine compounds of Formula I in high yield and high purity. In particular, the provides a process for the preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamde, its hemisuccinate salt and polymorph (Form A).

  本发明提供了2,4,6-三氟-N-[6-(1-甲基哌啶-4-羰基)-吡啶-2-基]-苯甲酰半琥酸盐的新型多晶形态（A型），其具有独特的X射线衍射图样和差示扫描量热分析曲线，以及独特的晶体结构。该多晶形态在药物组合物中具有用途，例如用于治疗和预防偏头痛。该发明还提供了一种高产率和高纯度合成Formula I中吡啶酰哌啶化合物的方法。具体来说，提供了一种制备2,4,6-三氟-N-[6-(1-甲基哌啶-4-羰基)-吡啶-2-基]-苯甲酰半琥酸盐和多晶形态（A型）的方法。
• [EN] PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LASMIDITAN ET D'UN INTERMÉDIAIRE DE SYNTHÈSE
  申请人：OLON SPA

  公开号：WO2021116979A1

  公开（公告）日：2021-06-17

  The present invention refers to a process for the preparation of Lasmiditan and of a synthesis intermediate of formula (II).

  本发明涉及一种用于制备拉司米他坦（Lasmiditan）和式（II）合成中间体的过程。
• Compositions And Methods Of Synthesis Of Pyridinolypiperidine 5-HT1F Agonists
  申请人：Carniaux Jean-Francois

  公开号：US20130072524A1

  公开（公告）日：2013-03-21

  The present invention provides a novel polymorph of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide (Form A) characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure. This polymorph is useful in pharmaceutical compositions, for example, for the treatment and prevention of migraine. The invention also provides a process for the synthesis of pyridinoylpiperidine compounds of Formula I in high yield and high purity. In particular, the provides a process for the preparation of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide, its hemisuccinate salt and polymorph (Form A).

  本发明提供了2,4,6-三氟-N-[6-(1-甲基哌啶-4-羰基)-吡啶-2-基]-苯甲酰半琥珀酸盐（A型）的新型多晶体形态，其具有独特的X射线衍射图案和差示扫描量热分析曲线，以及独特的结晶结构。该多晶体形态在制备药物组合物方面有用，例如用于治疗和预防偏头痛。本发明还提供了一种高产率和高纯度合成Formula I的吡啶基哌啶化合物的方法。特别地，本发明提供了制备2,4,6-三氟-N-[6-(1-甲基哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺、其半琥珀酸盐和多晶体形态（A型）的方法。
• PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE
  申请人：OLON S.p.A.

  公开号：EP4073056A1

  公开（公告）日：2022-10-19
• US8697876B2
  申请人：——

  公开号：US8697876B2

  公开（公告）日：2014-04-15